Test Price
1,500 AED✅ Home Collection Available
NRAS Mutation Analysis (Codons 12, 13, and 61) – Genetics Test for Cancer Therapy Guidance – 1500 AED – DHA Licensed
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
Premium Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval – temperature-controlled from your UAE hospital.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The NRAS Mutation Analysis (Codons 12, 13, and 61) is a targeted molecular test that detects activating single‑nucleotide variants in the NRAS oncogene, critical for guiding anti‑EGFR therapy in colorectal cancer and for prognostication in melanoma and acute myeloid leukemia. It employs polymerase chain reaction (PCR) amplification followed by bidirectional Sanger sequencing, delivering allele‑specific sensitivity >99% on formalin‑fixed paraffin‑embedded (FFPE) tumor tissue.
| Feature | Our NRAS Test | Closest Alternative (NGS Panel) |
|---|---|---|
| Methodology | PCR + Bidirectional Sanger Sequencing | Next‑Generation Sequencing (multi‑gene) |
| Analytical Sensitivity | >99% for codon 12/13/61 mutations | ~95–98% (depends on depth) |
| Turnaround Time | 6 working days | 10–14 working days |
| Cost | 1500 AED | 3500+ AED |
| Focus | Single‑gene, expert‑verified for NRAS | Broad panel, may miss low‑level NRAS |
Physician Insight & Safety Protocols
“As a consultant in medical genetics, I understand that waiting for genetic test results can be overwhelming. The NRAS mutation analysis provides vital information that helps personalize cancer treatment planning, potentially avoiding ineffective therapies. Please remember that this test result must be interpreted alongside your full clinical picture; do not discontinue any prescribed medication without consulting your doctor.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Clinical Advisory
Do not discontinue prescribed medication without consulting your doctor.
Safety Exclusion Criteria & Red Flags
- Exclusion: FFPE blocks with less than 10% tumor content – may yield false‑negative results.
- Exclusion: Fresh bone marrow aspirates are preferred for haematological malignancies; this test is optimized for solid tumour tissue.
- Exclusion: Not intended for asymptomatic population screening; genetic counselling is recommended before testing.
- Emergency Red Flags: If you experience severe pain, bleeding, or signs of infection at the original biopsy site, seek immediate medical attention.
- Patient safety: This test must be ordered by a licensed physician; results require correlation with clinical and radiological findings.
Patient FAQ & Clinical Guidance
1. What does a positive NRAS mutation result mean for my cancer treatment?
A positive NRAS mutation indicates resistance to anti‑EGFR therapies and guides alternative targeted treatment strategies. In colorectal cancer, it predicts lack of response to cetuximab or panitumumab, so your oncologist will consider chemotherapy or other targeted agents.
2. How is the FFPE tissue block collected and shipped safely?
We coordinate with your hospital’s pathology department to courier the block at room temperature securely using a prepaid, trackable kit. The paraffin block remains stable without refrigeration, and we ensure chain‑of‑custody documentation throughout transit.
3. How long does it take to receive the NRAS results in UAE?
Results are typically available within 6 working days from sample receipt at our lab. This includes DNA extraction, PCR amplification, Sanger sequencing, and a comprehensive report signed by a molecular geneticist. Expedited reporting may be arranged for urgent clinical needs.
UAE Regulatory & Data Privacy Adherence
Data Privacy & Health Information Protection: All patient data is handled in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Your genetic information is encrypted, stored securely, and accessed only by authorized personnel for clinical purposes. Our laboratory is licensed by the Dubai Health Authority (DHA License No. 1143) and operates under the strictest quality and confidentiality standards.
Clinical & Logistical Metadata
| Test Name | NRAS Mutation Analysis (Codons 12, 13, and 61) |
| Price (AED) | 1500 AED |
| Turnaround Time | 6 working days |
| Sample Type / Matrix | Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Block – Archival Specimen |
| Methodology Used | PCR + Bidirectional Sanger Sequencing |
| ICD-10-CM Code | C18.9 (Malignant neoplasm of colon, unspecified) |
| LOINC Code | 48767-7 (NRAS gene mutations found [Identifier] in Tissue by Sequencing) |
| DHA Facility License & Laboratory Address | DHA License No. 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians